Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies

Heiner Wedemeyer, Xavier Forns, Christophe Hézode, Samuel S Lee, Astrid Scalori, Athina Voulgari, Sophie Le Pogam, Isabel Nájera and James A Thommes

PLOS ONE, 2016, vol. 11, issue 1, 1-20

Abstract: Most patients with chronic hepatitis C virus (HCV) genotype 1 infection who have had a previous null response (

Date: 2016
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0145409 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 45409&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0145409

DOI: 10.1371/journal.pone.0145409

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().